ACN Newswire
Read More

Aohua Endoscopy, the Leading Endoscope Company Invested by Legend Capital, Successfully Listed on China’s STAR Market

indie
3 minutes

HONG KONG, Nov 15, 2021 - (ACN Newswire via SEAPRWire.com) - On November 15th, Aohua Endoscope (688212.SH), which invested by Legend Capital, was successfully listed on the Science and Technology Innovation Board (STAR Market) in China. The total number of public offering of Aohua Endoscopy is 33.34 million shares with an offering price set at RMB22.5 per share. Founded in 1994, Aohua Endoscopy is one of the earliest high-tech enterprises in China that mainly engaged in the R&D, production and sales of endoscope and endoscopic consumables. Aohua Endoscopy's vision is "Becoming the world's leading provider of overall endoscopy solutions". In the course of over 20 years of research and innovation, Aohua Endoscopy has developed a full range of endoscopy products used in various clinical sections, including gastroenterology department, pneumology department, otorhinolaryngologic department, gynecology department and ED.Legend Capital exclusively invested in Aohua Endoscopy's Series B financing in 2014 and co-led its Series C financing in 2016, becoming its largest institutional investor. After the investment, Legend Capital provided all-round support and assistance in its follow-up...

JCN Newswire
Read More

NEC’s artificial intelligence (AI) supports doctors to determine if colorectal lesions are potentially neoplastic

ruth
4 minutes

TOKYO, Jul 14, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (NEC; TSE: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic. NEC developed a new technology, called "Cx20," while seeking to assist in the early detection of colorectal lesions. Cx20 has already met the requirements for CE marking, a European safety, health and environmental protection standard, and will be integrated in the medical device AI diagnostic support software "WISE VISION Endoscopy" (1), with sales expected to start in Europe later this year.The Cx20 function supports the identification of disease. During examinations, suspected lesions are automatically detected through video taken by endoscope devices. Doctors then extract still images (left) and analysis results are soon displayed (right)This software connects and interacts with existing endoscopic equipment and automatically notifies users if a lesion is possibly neoplastic based on images captured during endoscopy procedures. The software then becomes an extra tool immediately available to assist endoscopists in the differentiation of lesions a...

JCN Newswire
Read More

NEC’s AI Supports Doctors to Detect Neoplasia in Barrett’s Esophagus during Endoscopic Procedures

ruth
7 minutes

TOKYO, May 28, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (NEC; TSE: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett's esophagus during endoscopic procedures. This is the world's first technology of its kind to comply with the requirements for CE mark labeling, a European safety, health and environmental protection standard (1), and is being released as WISE VISION Endoscopy, where it will soon be available in Europe to help doctors in the detection of Barrett's neoplasia (2). Provided by Professor Pradeep Bhandari: "Once the neoplasia is found, the system takes a still image and transfers it to the top right corner of a screen as a reference image for endoscopists. It also has a heat map which shows the area of the AI-predicted neoplasia."This software is connected to endoscopy processors and automatically notifies users of potential Barrett's neoplasia from images captured during endoscopic procedures.Barrett's esophagus is a pre-cancerous condition in which the inner lining of the esophagus is replaced by a lining that resembles that of the stomach. Worldwide prevalence of Barrett's esophagus is 1% of...

JCN Newswire
Read More

NEC Releases ‘WISE VISION Endoscopy’ in Europe and Japan

ruth
4 minutes

TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe. This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures. Colorectal cancer is the most common cancer in Japan(1), and the second most common in Europe(2). Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress the progression to cancer by detecting and removing lesions at the polyp stage during endoscopy procedures. However, polyps need to be found with the eye of an endoscopist, and are often difficult to detect because of their size and shape, causing approximately 24%(3) to be missed, thereby delaying detection. NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue. NEC has now developed software that can automatically mark potential lesions based on the use of AI to learn from endosco...